文献速递肝病

NIS2+™:基于血液的生物标志物NIS4®技术的优化用于检测高危NASH的前瞻性衍生与验证研究

NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
PubMed 文献 · J Hepatol · 2023-05-22

NIS2+™是NIS4®的优化版血液无创检测,用于在有代谢危险因素的患者中检测高危NASH(NAFLD活动度评分≥4且纤维化分期≥2)。训练队列来自GOLDEN-505试验(n=198),验证队列(n=684)和测试队列(n=2,035)来自RESOLVE-IT试验。测试队列中NIS2+™的AUROC为0.813,高于NIS4®的0.792(p=0.0002)、Fibrosis-4的0.653(p<0.0001)和丙氨酸氨基转移酶的0.699(p<0.0001),且不受年龄、性别、BMI或2型糖尿病状态影响。

要点

  • NIS2+™由miR-34a-5p和YKL-40组成,并加入性别及性别×miR-34a-5p参数以校正性别效应。
  • 测试队列中NIS2+™的AUROC为0.813,高于NIS4®的0.792(p=0.0002)。
  • NIS2+™评分不受年龄、性别、BMI或2型糖尿病状态影响,性能稳健。

核心结论

  • NIS2+™是NIS4®技术的稳健优化,用于检测高危NASH。
  • NIS2+™在有代谢危险因素的患者中检测高危NASH的性能优于NIS4®及其他无创肝脏检测,且不受患者特征影响。

研究设计与样本

  • 前瞻性衍生与验证研究:训练队列来自GOLDEN-505试验(n=198),验证队列(n=684)和测试队列(n=2,035)来自RESOLVE-IT试验。
  • 构建匹配良好的亚组以避免建模和分析评分稳健性时的潜在混杂效应。
  • 使用逻辑回归训练模型检测高危NASH,并用贝叶斯信息准则比较模型。

主要发现

  • 训练队列比较NIS4®生物标志物所有组合后,NIS2(miR-34a-5p、YKL-40)被确定为最佳参数组合。
  • 验证队列中为校正性别对miR-34a-5p的影响,加入性别和性别×miR-34a-5p参数,形成NIS2+™。
  • 测试队列中NIS2+™的AUROC为0.813,NIS4®为0.792(p=0.0002),Fibrosis-4为0.653(p<0.0001),丙氨酸氨基转移酶为0.699(p<0.0001)。
  • NIS2+™评分不受年龄、性别、BMI或2型糖尿病状态影响。

关键数值与推荐

  • 高危NASH定义为非酒精性脂肪性肝病活动度评分≥4且显著纤维化(分期≥2)。
  • 训练队列n=198,验证队列n=684,测试队列n=2,035。
  • 测试队列AUROC:NIS2+™ 0.813 vs NIS4® 0.792(p=0.0002),vs Fibrosis-4 0.653(p<0.0001),vs 丙氨酸氨基转移酶0.699(p<0.0001)。

临床怎么用

  • NIS2+™在有代谢危险因素的患者中检测高危NASH性能稳健且可靠,是有望大规模应用于临床实践和临床试验的候选工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: NIS4® is a blood-based non-invasive test designed to effectively rule in/rule out at-risk non-alcoholic steatohepatitis (NASH), defined as non-alcoholic fatty liver disease activity score ≥4 and significant fibrosis (stage ≥2), among patients with metabolic risk factors. Robustness of non-invasive test scores across characteristics of interest including age, type 2 diabetes mellitus, and sex, and optimised analytical aspects are critical for large-scale implementation in clinical practice. We developed and validated NIS2+™, an optimisation of NIS4®, specifically designed to improve score robustness. METHODS: A well-balanced training cohort (n = 198) included patients from the GOLDEN-505 trial. The validation (n = 684) and test (n = 2,035) cohorts included patients from the RESOLVE-IT trial. Well-matched subgroups were created to avoid potential confounding effects during modelling and analysis of score robustness. Models were trained using logistic regressions for at-risk NASH detection and compared using Bayesian information criteria. Performance of NIS2+™ was compared with that of NIS4®, Fibrosis-4, and alanine aminotransferase using area under the receiver operating characteristic curve, and robustness was analysed through score distribution. RESULTS: Using the training cohort to compare all combinations of NIS4® biomarkers, NIS2 (miR-34a-5p, YKL-40) was identified as the best combination of parameters. To correct for the sex effect on miR-34a-5p (validation cohort), sex and sex ∗ miR-34a-5p parameters were added, creating NIS2+™. In the test cohort, NIS2+™ exhibited a statistically higher area under the receiver operating characteristic curve (0.813) vs. NIS4® (0.792; p = 0.0002), Fibrosis-4 (0.653; p <0.0001), and alanine aminotransferase (0.699; p <0.0001). NIS2+™ scores were not affected by age, sex, BMI, or type 2 diabetes mellitus status, providing robust clinical performances irrespective of patient characteristics. CONCLUSION: NIS2+™ constitutes a robust optimisation of NIS4® technology for the detection of at-risk NASH. IMPACT AND IMPLICATIONS: The development of non-invasive tests for accurate, large-scale detection of patients with at-risk non-alcoholic steatohepatitis (NASH; defined as NASH with non-alcoholic fatty liver disease activity score ≥4 and fibrosis stage ≥2) - who are at higher risk for disease progression and for developing liver-related life-threatening outcomes - is critical for identifying this patient population in the clinical setting and improving the screening process of NASH clinical trials. We report the development and validation of NIS2+™, a diagnostic test designed as an optimisation of NIS4® technology, a blood-based panel currently used to detect at-risk NASH in patients with metabolic risk factors. NIS2+™ showed improved performance for the detection of at-risk NASH compared with NIS4® and other non-invasive liver tests that was not impacted by patients' characteristics of interest, such as age, sex, type 2 diabetes mellitus, BMI, dyslipidaemia, and hypertension. This makes NIS2+™ a robust and reliable tool for the diagnosis of at-risk NASH among patients with metabolic risk factors, and an effective candidate for large-scale implementation in clinical practice and clinical trials.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Ratziu V, Magnanensi J, et al. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study. J Hepatol. 2023. PMID: 37224923. doi:10.1016/j.jhep.2023.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。